Calidi Biotherapeutics(CLDI) - 2023 Q1 - Quarterly Report

For the quarterly period ended March 31, 2023 Delaware 86-2967193 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(g) of the Act: None Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ As of May 15, 2023, there were 4,128,024 shares of the Company's Class A common stock, par value $0.0001 per share, and 5,750,000 shares of the Company's Class B common stock, par value$0.0001, issued an ...